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Received August 31, 2011; accepted December 16, 2011AbstractBackground: CharcoteMarieeTooth disease type 1A (CMT1A) is the most common type of hereditary neuropathy. The demyelinating
pathology of CMT1A results in significant nerve conduction slowing such that a nerve conduction study (NCS) is important in the
clinical assessment of CMT1A. In this study, we analyzed and reported the electrophysiological features of a large Taiwanese cohort with
CMT1A.
Methods: We retrospectively analyzed the NCS data of 106 Taiwanese patients with CMT1A. We also compared the electrophysiological
parameters of the CMT1A patients with those of 20 patients with early-onset CharcoteMarieeTooth disease type 1B (CMT1B).
Results: The patients with CMT1A had a significant but variable degree of slowed nerve conduction. The median motor nerve conduction
velocities (MNCVs) varied from 10.0 to 37.3 m/s in the entire CMT1A cohort but were more concordant in patients within a family ( p< 0.001).
In each patient, the MNCVs among different nerves were concordant ( p< 0.001), and the MNCVs tended to remain steady longitudinally.
Moreover, younger patients had a slower MNCV than older patients within the CMT1A population ( p< 0.001). The average median MNCV
was significantly faster in the CMT1A patients than in the CMT1B patients (21.8 6.2 m/s and 16.3 3.6 m/s; p< 0.001).
Conclusion: This study provides basic electrophysiological knowledge about CMT1A in Taiwan. The findings also suggest that the electro-
physiological variability in the CMT1A cohort may be at least partially attributable to unknown genetic factors. These data emphasize the role of
MNCV in the clinical assessment of CMT1A. A median or ulnar MNCV below 38 m/s can be a sensitive criterion for supporting the diagnosis of
CMT1A. A median MNCV can sometimes help to distinguish CMT1A from CMT1B, and CMT1A should be considered in patients with median
MNCVs near or above 24 m/s. Moreover, the MNCV may to some degree reflect the severity of CMT1A.
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CharcoteMarieeTooth (CMT) disease, also called heredi-
tary motor and sensory neuropathy, is the most common* Corresponding author. Dr. Yi-Chung Lee, Neurological Institute, Taipei
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doi:10.1016/j.jcma.2012.03.005hereditary peripheral neuropathy, with an estimated prevalence
of one in 2500.1 The syndrome was first described by Jean-
Martin Charcot and Pierre Marie in France and Henry Howard
Tooth in England in 1886. The characteristic features include
progressive distal muscle atrophy and weakness, decreased
sensation, depressed tendon reflexes, and foot deformities.
The syndrome can be further classified according to the age
at disease onset, inheritance patterns, and electrophysiological
or pathological features. CMT type 1 (CMT1) is the most
common type and consists of a genetically heterogeneous grouphinese Medical Association. All rights reserved.
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them, CMT1A is the most frequent subtype, 53.6e70.7% of
CMT patients belonging to the CMT1A group.2e4 CMT1A
is caused by a 1.5-Mb DNA duplication on chromosome
17p11.2e12 that includes the peripheral myelin protein 22 gene
(PMP22).5,6 CMT type 1B (CMT1B), another rarer type of
CMT1, results from a mutation in the myelin protein zero gene
(MPZ ).7
Nerve conduction studies (NCSs) play an important role in
diagnosing and assessing the severity of CMT1A. Patients
with CMT1A usually have a median motor nerve conduction
velocity (MNCV) of less than 38 m/s,8 and slowing of nerve
conduction can perfectly distinguish CMT1A patients from
those that are unaffected.9 Moreover, the muscle wasting and
weakness seen in CMT1A patients can correlate well with
compound muscle action potential (CMAP) amplitudes;10
thus, NCSs can be used to monitor the clinical severity of
CMT1A.
It is interesting that CMAP rather than MNCV correlates
well with motor function in CMT1A patients.10 This suggests
that their disability might come from secondary axonal
damage rather than demyelination,11,12 although the principal
neuropathological change in CMT1A is peripheral demyelin-
ation. The NCVs in patients with CMT1A are usually maxi-
mally slowed before age 5 years,10 and precede the onset of
weakness, also suggesting that demyelination is not the major
determinant of disability in CMT1A.
Because a large degree of phenotypic variation is common
in CMT1, NCSs may be more helpful than clinical examination
in identifying CMT1A. Although NCSs play an important role
in the clinical survey of CMT1A, there are as yet no referenced
electrophysiological data on CMT1A in the Taiwanese pop-
ulation or other Chinese populations. In this study, we char-
acterize and report the electrophysiological features of a large
Taiwanese CMT1A cohort of Han-Chinese origin.
2. Methods2.1. SubjectsWe retrospectively analyzed the demographic and NCS
data of a consecutive series of 106 Taiwanese patients of Han-
Chinese origin with CMT1A that had been recruited in the
previous 20 years from the Neurology Service, Taipei Veterans
General Hospital, Taiwan. These 106 patients with CMT1A
came from 81 families, and all underwent NCS at least once.
All of the patients harbored a duplication of the 1.5-Mb DNA
region on chromosome 17p11.2, as demonstrated by the short
tandem repeat polymerase chain reaction method.13 Twenty
patients with MPZ mutations were enrolled as the CMT1B
group, and most of these subjects had previously been
described in an earlier study.14
NCSs were performed by standard techniques utilizing
a Medelec MS25 electromyograph (Mistro, Surrey, U.K.) with
surface electrode stimulations and recordings.15 Distal and
proximal motor latencies and CMAP amplitudes were recorded
from the median, ulnar, peroneal, and tibial nerves in thesubjects studied. Sensory nerve action potential (SNAP)
amplitudes and distal latencies (DLs) were recorded from the
median, ulnar, and sural nerves. NCVs were calculated by
standard techniques. NCS data from the first study performed
with the patients who underwent NCS more than once were
included in our statistical analysis. The study was approved by
the Institutional Review Board of Taipei Veterans General
Hospital (2011-06-17IC).2.2. Statistical analysisThe mean and standard deviation of each electrophysio-
logical parameter (DL, MNCV, and CMAP amplitude) were
calculated for the median, ulnar, peroneal, and tibial nerves.
For the patients with CMT1A, the MNCV and CMAP ampli-
tudes of the median and ulnar nerves were compared between
men and women using Student t tests. The CMT1A patients
were further divided into two groups based on the cut-off
value of 20 years of age. The MNCV and CMAP amplitudes
of the median and ulnar nerves were then compared between
the subjects older and younger than 20 years of age using
Student t tests. Seven subjects underwent two NCSs at
longitudinal follow-ups. The median MNCVs of each subject
at follow-up and at the first visit were compared using the
Wilcoxon signed rank test. The associations between age and
MNCVs or CMAP amplitudes of different nerves were
analyzed by Pearson’s correlation. Similarly, we evaluated the
relationships between median MNCVs and ulnar MNCVs, as
well as between median and peroneal MNCVs.
Among the 106 CMT1A patients, 42 were consanguinities
recruited from 17 families. We then compared the median
MNCVs of the index case and the data of their relatives
from the same family using Pearson’s correlation. We also
compared the electrophysiological data of the patients with
CMT1A with those of the 20 patients with CMT1B using
Student t tests. All of the statistical analyses were performed
with Predictive Analytics Suite Workstation (PASW) statistics,
version 18.0.0 (SPSS Inc., Chicago, IL, USA). A two-tailed
p< 0.05 was defined as statistically significant.
3. Results3.1. General findingsWe analyzed the NCS data of the 106 patients with
CMT1A. Fifty-three patients (50%) were male, and the mean
age at examination was 39.58 18.13 years (range 3e81
years). Eleven patients underwent more than one NCS (time
interval 6e93 months). For the patients receiving multiple
NCS examinations, the first NCS dataset was used for statis-
tical analysis.
The median MNCV, CMAP amplitude, and motor latencies
were the most frequently detectable electrophysiological
parameters (95.28%), and the median MNCVs of the 106
CMT1A patients were all below 38 m/s (range 10.0e37.3 m/s).
The MNCVs, CMAP amplitudes, and motor DLs of our study
participants are shown in Table 1. The SNAP amplitudes were
Table 1
Motor nerve conduction findings in 106 patients with CharcoteMarieeTooth
disease type 1A.
Range Mean SD Normal value
Median nerve (n¼ 101, undetectable¼ 5)
DL (ms) 7.00e19.30 11.14 2.14 < 4.80
MNCV (m/s) 10.00e37.30 21.76 6.15 > 50.70
CMAP (mV) 0.10e10.00 3.83 2.35 > 5.70
Ulnar nerve (n¼ 98, undetectable¼ 8)
DL (ms) 4.80e17.50 8.26 2.05 < 3.45
MNCV (m/s) 7.40e36.80 20.00 5.57 > 46.70
CMAP (mV) 0.20e8.00 3.63 1.85 > 6.00
Peroneal nerve (n¼ 38, undetectable¼ 68)
DL (ms) 6.40e24.10 10.90 3.36 < 6.00
MNCV (m/s) 9.60e28.20 18.54 4.90 > 42.00
CMAP (mV) 0.10e3.50 1.13 0.96 > 1.70
Tibial nerve (n¼ 58, undetectable¼ 48)
DL (ms) 5.70e17.30 9.41 2.83 < 7.10
MNCV (m/s) 11.40e33.70 20.57 5.59 > 41.50
CMAP (mV) 0.10e6.60 1.62 1.65 > 3.50
CMAP¼ compound muscle action potential; DL¼ distal latency;
MNCV¼motor nerve conduction velocity; SD¼ standard deviation.
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median and ulnar nerves of 100 patients (95.24%). In the
remaining five patients, the sensory DLs were 7.96 1.94 ms
in the median nerves and 8.83 3.68 ms in the ulnar nerves,
and the SNAP amplitudes were 2.34 2.21 mcV in the median
nerves and 5.53 2.30 mcV in the ulnar nerves. The sural
nerve SNAP amplitudes could not be determined in 105
patients (99.06%).
The median MNCV was significantly correlated to the
ulnar or peroneal MNCV (r¼ 0.835 and 0.795, respectively;
p< 0.001), indicating that the median MNCV was concordant
with the ulnar or peroneal MNCV in CMT1A.3.2. GenderThere was no significant difference in the MNCV and
CMAP amplitudes for the median and ulnar nerves between
the male and female patients (median MNCV, p¼ 0.593;
median CMAP amplitudes, p¼ 0.978; ulnar MNCV,
p¼ 0.409; ulnar CMAP amplitudes, p¼ 0.903).3.3. Age at examinationThe median and ulnar MNCVs positively correlated with
patient age at the time of the NCS examinations (r¼ 0.331 and
0.471, respectively; p0.001; Fig. 1A). The CMAP ampli-
tudes at the median nerves had an inverse relationship with age
(r¼0.267, p¼ 0.008), while the ulnar CMAP amplitudes
did not significantly correlate with age (r¼0.045,
p¼ 0.664; Fig. 1B). We used an age of 20 years to dichoto-
mize our patients into younger and older groups. The median
and ulnar MNCVs were significantly lower in the younger
group ( p 0.001; Table 2). However, there was no significantdifference in the median and ulnar CMAP amplitudes between
the two groups.3.4. Longitudinal electrophysiological changeEleven patients had more than one NCS (with time intervals
from 6 to 93 months), and only seven of them had a detectable
MNCV on two different NCS assessments. There were no
significant longitudinal changes in the median MNCV and
CMAP amplitudes of these seven patients in the two exami-
nations ( p¼ 0.6 and 0.735, respectively).3.5. Intrafamilial electrophysiological variationForty-two patients from 17 families had at least one relative
who also participated in this study. Three patients were
excluded because their median MNCVs were undetectable. The
mean median MNCV in the 16 families was 22.59 6.02 m/s
(range 11.3e34.7 m/s). Among each family, the average vari-
ation of the median MNCV was 3.15 2.54 m/s (range
0.4e9.17 m/s). In spite of a small degree of intrafamilial vari-
ation, there was a moderate correlation (r¼ 0.76) between the
median MNCVs of subjects from the same family ( p< 0.001;
Fig. 2).3.6. Comparison with CMT1B patientsWe compared the NCS parameters of the CMT1A patients
with those of the 20 CMT1B subjects from our population.
All those patients harboring MPZ mutations had early-onset
neuropathy.16 The comparison between CMT1A and CMT1B
is shown in Table 3. Compared with the patients with CMT1B,
the MNCVs of the median and ulnar nerves were significantly
higher in patients with CMT1A ( p 0.001; Fig. 3).
4. Discussion
In this study, we performed an electrophysiological analysis
of 106 patients with CMT1A and found that all of them had
a significant but variable degree of slowed nerve conduction.
The median MNCVs varied from 10.0 to 37.3 m/s in the whole
CMT1A cohort, but were more concordant in patients within
a family. In each patient, there was a concordance between
different nerve MNCVs, and the MNCVs tended to remain
steady longitudinally. Moreover, within the CMT1A pop-
ulation, younger patients had slower NCVs than older patients.
Further, early-onset patients with CMT1B usually had lower
median MNCVs than those with CMT1A. These findings may
have the following implications.
First, the median or ulnar MNCV can be a sensitive
parameter to support the diagnosis of CMT1A. Theoretically,
CMT1A is a generalized demyelinating neuropathy with
a uniform slowing of conduction, but in clinical practice not
all nerve conduction is detectable. In our study, all the nerves
of the 106 CMT1A patients had significantly decreased
NCVs, but in many cases sensory or motor nerve conduction
could not be appropriately elicited. Among the nerves
Fig. 1. Scatter plot diagrams with Pearson’s correlation analysis between the age at examination and the median and ulnar MNCVs (A, B) and median and ulnar
CMAP amplitudes (C, D). CMAP ¼ compound muscle action potential; MNCV ¼ motor nerve conduction velocity.
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the median or ulnar nerve could be detected in more than 90%
of the CMT1A patients, and the median or ulnar MNCVs
were all below 38 m/s. The normal lower limits of median or
ulnar MNCVs in our electromyography laboratory were 50.7
and 46.7 m/s, respectively. The diagnosis of CMT1A could beTable 2
Electrophysiological comparison between two age groups.
Younger group
( 20 years old)
Older group
(> 20 years old)
p
Number of patients 22 84
Median MNCV (m/s) 18.00 5.13 22.83 6.05 0.001*
Ulnar MNCV (m/s) 14.01 3.73 21.53 4.92 < 0.001*
Median CMAP (mV) 3.86 2.15 3.72 2.39 0.822
Ulnar CMAP (mV) 2.90 1.79 3.77 1.83 0.075
Data are shown as mean standard deviation.
*A p 0.05 was statistically significant.
CMAP¼ compound muscle action potential; MNCV¼motor nerve conduc-
tion velocity.
Fig. 2. The correlation of the median motor nerve conduction velocity
(MNCV) between index cases and family members.
Table 3
Comparison between patients with CharcoteMarieeTooth type 1A disease (CMT1A) with 17p11.2 duplication and early-onset type 1B disease (CMT1B) with
MPZ mutation.
CMT1A CMT1B p
Number of patients 106 20
Age at examination 39.58 18.13 (3e81) 36.15 17.61 (9e77) 0.438
Median MNCV (m/s) 21.76 6.15 (10.00e37.30) 16.28 3.59 (8.90e24.00) < 0.001*
Ulnar MNCV (m/s) 20.00 5.57 (7.40e36.80) 15.49 3.22 (9.40e23.30) < 0.001*
Median CMAP (mV) 3.83 2.35 (0.10e10.00) 3.93 2.25 (0.40e9.80) 0.869
Ulnar CMAP (mV) 3.63 1.85 (0.20e8.00) 3.34 1.73 (0.2e6.4) 0.535
Data are shown as the mean standard deviation. Numbers in parentheses refer to ranges.
*A p 0.05 was statistically significant.
CMAP¼ compound muscle action potential; MNCV¼motor nerve conduction velocity.
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38 m/s.
Second, NCVs in patients with CMT1A are also modified
by other genetic factors in addition to the PMP22 duplication.
In addition to significantly slowed nerve conduction, a highly
individual variation in NCVs was reported in several different
CMT1A populations.9,17 Our study revealed that NCVs in
patients from the same family tended to be concordant despite
a high variation between NCVs across the entire CMT1A
population. Consequently, this suggests that NCV slowing is
not solely determined by PMP22 duplication, but is also
modified by other genetic factors shared by the same family.
Further study to identify these NCV-modifying genes in
CMT1A might increase the knowledge of the pathophysiology
of CMT1A and increase the options for developing new
therapeutic strategies.
Third, the MNCVs may reflect the severity of the
congenital myelin defects in the patients with CMT1A. Our
study showed that MNCVs in patients with CMT1A tended to
remain the same longitudinally, a phenomenon that has also
been reported in CMT1A patients in other populations.18e20Fig. 3. The distribution of median and ulnar motor nerve conduction velocity
(MNCV) in patients with Charcot–Marie–Tooth disease type 1A (CMT1A)
and 1B (CMT1B). The means of the median and ulnar MNCVs in CMT1A
patients were significantly higher than those in CMT1B patients. The box blot
shows the median and the 1st and 3rd quartiles. The circles denote outliers.Myelin plays an essential role in facilitating nerve conduc-
tion. Thus, the steady MNCV values could be representative of
the intactness of the myelin. Although we do not have in this
retrospective study precise data addressing patient age when
clinical onset occurred, the patient age at the first NCS could
be positively correlated to the age at clinical onset because
patients with an earlier onset often sought medical help and
underwent NCS earlier than those who had a later onset.
Therefore, a lower MNCV in younger patients with CMT1A in
our study could be interpreted as “CMT1A patients with an
earlier clinical onset have lower MNCVs.” In addition to an
earlier clinical onset, a lower median MNCV is also associated
with a more severe disease course.17,18,21
Compared with patients with CMT1A, thosewith early-onset
CMT1B usually had lower MNCVs. The means of the median
and ulnar MNCVs of the CMT1B patients were significantly
lower than those of the CMT1A patients in our study, which
was consistent with previous reports.18,22 The ranges of the
median MNCVs of our CMT1A and CMT1B patients were
10e37.3 m/s and 8.9e24 m/s, respectively. Therefore, CMT1B
should be considered first in the CMT1 patients with median
MNCVs near or below 10 m/s, and CMT1A should be consid-
ered in CMT1 patients with median MNCVs near or above
24 m/s in patients of Han-Chinese origin.
In conclusion, we analyzed and reported the electrophysi-
ological features of a large Taiwanese cohort with CMT1A. In
addition to providing basic knowledge on CMT1A in our
population, our findings also suggest that unknown genetic
factors may modify CMT1A, and emphasize the role of
MNCVs in the clinical assessment of CMT1A as follows:
a median or ulnar MNCV below 38 m/s can be a sensitive
criterion for supporting the diagnosis of CMT1A, a median
MNCV can sometimes help to distinguish CMT1A from
CMT1B, and the MNCV may reflect the severity of CMT1A.References
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